

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 10 of 34 returned.☐ 1. Document ID: US 20030113339 A1

L1: Entry 1 of 34

File: PGPB

Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030113339

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030113339 A1

TITLE: Methods to improve immunogenicity of antigens and specificity of antibodies

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fitzpatrick, Judith	Englewood	NJ	US	
Lenda, Regina	Wesley Hills	NY	US	

US-CL-CURRENT: 424/184.1; 435/70.21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
Image												

☐ 2. Document ID: US 20030095976 A1

L1: Entry 2 of 34

File: PGPB

May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030095976

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030095976 A1

TITLE: Methods to improve immunogenicity of antigens and specificity of antibodies

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fitzpatrick, Judith	Englewood	NJ	US	
Lenda, Regina	Wesley Hills	NY	US	

US-CL-CURRENT: 424/184.1; 435/70.21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc
Image												

☐ 3. Document ID: US 20030086939 A1

L1: Entry 3 of 34

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030086939
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030086939 A1

TITLE: Methods to improve immunogenicity of antigens and specificity of antibodies

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fitzpatrick, Judith	Englewood	NJ	US	
Lenda, Regina	Wesley Hills	NY	US	

US-CL-CURRENT: 424/185.1; 435/70.21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc
Image												

☐ 4. Document ID: US 20030077287 A1

L1: Entry 4 of 34

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077287
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030077287 A1

TITLE: Methods to improve immunogenicity of antigens and specificity of antibodies

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fitzpatrick, Judith	Englewood	NJ	US	
Lenda, Regina	Wesley Hills	NY	US	

US-CL-CURRENT: 424/184.1; 435/70.21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc
Image											

☐ 5. Document ID: US 20030069195 A1

L1: Entry 5 of 34

File: PGPB

Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030069195
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030069195 A1

TITLE: Suppression of polymorphic alleles

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Farrar, Gwendyth Jane	Monkstown		IE	
Humphries, Peter	Cabinteeley		IE	
Millington-Ward, Sophia	Glasnevin		IE	
Francis, Paul	Dublin		IE	

US-CL-CURRENT: 514/44; 435/455

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc
Image											

☐ 6. Document ID: US 20030049710 A1

L1: Entry 6 of 34

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049710
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049710 A1

TITLE: Method for evaluating inhibition of aspartic proteases

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Northrup, Dexter B.	Madison	WI	US	

US-CL-CURRENT: 435/23

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc
Image											

☐ 7. Document ID: US 20020061549 A1

L1: Entry 7 of 34

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061549
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020061549 A1

TITLE: Stabilized proteins

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Marshall, Christopher P.	Brooklyn	NY	US	
Hoffman, Alexander	Los Angeles	CA	US	
Errico, Joseph P.	Far Hills	CA	US	
Marshall, Paul B.	Munich		DE	

US-CL-CURRENT: 435/68.1; 435/198, 530/350, 530/388.1, 530/399

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KWIC	Draw Desc
------	-----------

☐ 8. Document ID: US 20020039726 A1

L1: Entry 8 of 34

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039726

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020039726 A1

TITLE: Melanins with improved ability to inhibit HIV replication

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Garger, Steven	Vacaville	CA	US	
Neidleman, Saul	Oakland	CA	US	

US-CL-CURRENT: 435/5; 424/278.1, 435/39, 514/2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KWIC	Draw Desc
------	-----------

☐ 9. Document ID: US 6455047 B1

L1: Entry 9 of 34

File: USPT

Sep 24, 2002

US-PAT-NO: 6455047

DOCUMENT-IDENTIFIER: US 6455047 B1

TITLE: Methods to improve immunogenicity of antigens and specificity of antibodies

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fitzpatrick; Judith	Tenafly	NJ		
Lenda; Regina	Wesley Hills	NY		

US-CL-CURRENT: 424/193.1; 424/175.1, 424/184.1, 424/194.1, 530/405, 530/409, 546/131

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Image									

KWIC	Draw Desc
------	-----------

☐ 10. Document ID: US 6440691 B1

L1: Entry 10 of 34

File: USPT

Aug 27, 2002

US-PAT-NO: 6440691

DOCUMENT-IDENTIFIER: US 6440691 B1

TITLE: Melanins with improved ability to inhibit HIV replication

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Garger, Jr.; Steven	Vacaville	CA		
Neidleman; Saul	Oakland	CA		

US-CL-CURRENT: 435/39; 435/5, 514/2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC	Draw Desc
Image											

Generate Collection

Print

Terms	Documents
tyr-tyr and (lipase or kinase or antibody or amylase or hormone receptor or protein)	34

Display Format: -

Change Format

[Previous Page](#)

[Next Page](#)

WEST

Generate Collection

Print

L2: Entry 3 of 9

File: USPT

Jun 29, 1999

DOCUMENT-IDENTIFIER: US 5916876 A

TITLE: Peptide inhibitors of leukocyte adhesion

Brief Summary Text (4):

The complement proteins collectively play a leading role in the immune system, both in the identification and in the removal of foreign substances and immune complexes, as reviewed by Muller-Eberhard, H. J., Ann. Rev. Biochem. 57: 321-347 (1988). Central to the complement system are the C3 and C4 proteins, which when activated covalently attach to nearby targets, marking them for clearance. In order to help control this process, a remarkable family of soluble and membrane-bound regulatory proteins has evolved, each of which interacts with activated C3 and/or C4 derivatives. The coagulation and inflammatory pathways are regulated in a coordinate fashion in response to tissue damage. For example, in addition to becoming adhesive for leukocytes, activated endothelial cells express tissue factor on the cell surface and decrease their surface expression of thrombomodulin, leading to a net facilitation of coagulation reactions on the cell surface. In some cases, a single receptor can be involved in both inflammatory and coagulation processes.

Brief Summary Text (7):

Endothelium exposed to "rapid" activators such as thrombin and histamine becomes adhesive for neutrophils within two to ten minutes, while endothelium exposed to cytokines such as tumor necrosis factor and interleukin-1 becomes adhesive after one to six hours. The rapid endothelial-dependent leukocyte adhesion has been associated with expression of the lipid mediator platelet activating factor (PAF) on the cell surface, and presumably, the appearance of other endothelial surface receptors. The slower cytokine-inducible endothelial adhesion for leukocytes is mediated, at least in part, by E-selectin that is synthesized by endothelial cells after exposure to cytokines and then transported to the cell surface, where it binds neutrophils. The isolation, characterization and cloning of E-selectin or ELAM-1 is reviewed by Bevilacqua, et al., in Science 243, 1160-1165 (1989). L-selectin, a peripheral lymph node homing receptor, also called "the murine Mel 14 antigen", "Leu 8", the "Leu 8 antigen" and "LAM-1", is another structure on neutrophils, monocytes, and lymphocytes that binds lymphocytes to high endothelial venules in peripheral lymph nodes. The characterization and cloning of the protein is reviewed by Lasky, et al., Cell 56, 1045-1055 (1989) (mouse) and Tedder, et al., J. Exp. Med. 170, 123-133 (1989).

Brief Summary Text (8):

P-selectin, also known as GMP-140 (granule membrane protein 140), or PADGEM, is a cysteine-rich and heavily glycosylated integral membrane glycoprotein with an apparent molecular weight of 140,000 as assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). P-selectin was first purified from human platelets by McEver and Martin, J. Biol. Chem. 259: 9799-9804 (1984). The protein is present in alpha granules of resting platelets but is rapidly redistributed to the plasma membrane following platelet activation, as reported by Stenberg, et al., J. Cell Bio. 101, 880-886 (1985). The presence of P-selectin in endothelial cells and its biosynthesis by these cells was reported by McEver, et al., Blood 70(5) Suppl. 1:355a, Abstract No. 1274 (1987). In endothelial cells, P-selectin is found in storage granules known as the Weibel-Palade bodies. (McEver, et al. J. Clin. Invest. 84: 92-99 (1989) and Hattori, et al., J. Biol. Chem. 264: 7768-7771 (1989)). P-selectin (called GMP-140 or PADGEM) has also been reported to mediate the interaction of activated platelets with neutrophils and monocytes by Larsen, et al., in Cell 59, 305-312 (October 1989) and Hamburger and McEver, Blood 75: 550-554 (1990).

WEST

Generate Collection

Print

L1: Entry 19 of 34

File: USPT

Aug 4, 1998

DOCUMENT-IDENTIFIER: US 5789540 A

TITLE: Anticoagulant peptides

Brief Summary Text (5):

Hirudin is a 65 residue polypeptide isolated from the salivary glands of leeches. It is an anticoagulant agent, which is a thrombin specific inhibitor. Although quite potent, clinical use of hirudin isolated from leech extracts seems unlikely because of its limited quantity, expense and allergic reactions which commonly follow administration of any foreign protein of this size.

Detailed Description Text (43):

The term "any amino acid" as used herein includes the naturally occurring amino acids as well as other "non-protein" .alpha.-amino acids commonly utilized by those in the peptide chemistry arts when preparing synthetic analogs of naturally occurring peptides. The naturally occurring amino acids are glycine, alanine, valine, leucine, isoleucine, serine, methionine, threonine, phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamic acid, glutamine, arginine, ornithine, and lysine. Examples of "non-protein" .alpha.-amino acids are norleucine, norvaline, alloisoleucine, homoarginine, thiaproline, dehydroproline, hydroxyproline (Hyp), homoserine, cyclohexylglycine (Chg), .alpha.-amino-n-butyric acid (Aba), cyclohexylalanine (Cha), aminophenylbutyric acid (Pba), phenylalanines substituted at the ortho, meta, or paraposition of the phenyl moiety with one or two of the following, a (C.sub.1 -C.sub.4) alkyl, (C.sub.1 -C.sub.4) alkoxy, halogen, or nitro groups or substituted with a methylenedioxy group, .beta.-2- and 3-thienylalanine, .beta.-2- and 3-furanylalanine, .beta.-2-, 3-, and 4-pyridylalanine, .beta.-(benzothienyl-2- and 3-yl)alanine, .beta.-(1- and 2-naphthyl)alanine, O-alkylated derivatives of serine, threonine, or tyrosine, S-alkylated cysteine, the O-sulfate ester of tyrosine, 3,5-diiodotyrosine and the D-isomers of the naturally occurring amino acids.

Detailed Description Text (56):

A.sub.9, Pro, Ala-Tyr, Ala-Cha, Tyr-Cha, Tyr-Leu, Ala-Phe, Tyr-Tyr;

Detailed Description Text (67):

A.sub.9, Tyr-Leu, Ala-Tyr, Tyr-Tyr, Ala-Phe, Ala-Cha or Pro;

Detailed Description Text (70):

The proteins of this invention can be prepared by a variety of procedures readily known to those skilled in the art. Such procedures include the solid phase sequential and block synthesis, gene cloning and combinations of these techniques. The solid phase sequential procedure can be performed using established automated methods such as by use of an automated peptide synthesizer. In this procedure an .alpha.-amino protected amino acid is bound to a resin support. The resin support employed can be any suitable resin conventionally employed in the art for the solid phase preparation of polypeptides, preferably polystyrene which has been cross-linked with from 0.5 to about 3 percent divinyl benzene, which has been either chloro-methylated or hydroxymethylated to provide sites for ester formation with the initially introduced .alpha.-amino protected amino acid.

Other Reference Publication (27):

Robson et al., Introduction to Proteins and Protein Engineering, Elsevier Science Publishers B.V., New York, pp. 323-325 (1986).

WEST Search History

DATE: Monday, August 04, 2003

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

L2 L1 and dna

9 L2

L1 tyr-tyr and (lipase or kinase or antibody or amylase or hormone receptor
or protein)

34 L1

END OF SEARCH HISTORY